| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 38.517 | 55.374 | 27.181 | 28.955 | 29.030 | 26.623 | 22.903 | 17.483 | 27.824 | 27.386 |
| Total Income - EUR | 38.517 | 55.374 | 27.181 | 28.955 | 29.030 | 27.771 | 22.903 | 17.483 | 27.824 | 27.386 |
| Total Expenses - EUR | 42.587 | 50.877 | 33.532 | 38.337 | 37.122 | 34.661 | 35.349 | 30.655 | 35.564 | 42.870 |
| Gross Profit/Loss - EUR | -4.070 | 4.497 | -6.351 | -9.382 | -8.092 | -6.890 | -12.446 | -13.172 | -7.740 | -15.483 |
| Net Profit/Loss - EUR | -5.225 | 3.944 | -6.623 | -9.671 | -8.382 | -7.156 | -12.602 | -13.313 | -8.018 | -15.757 |
| Employees | 2 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Check the financial reports for the company - Elpiramyd 2008 Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 47.349 | 30.192 | 27.836 | 28.049 | 13.570 | 13.749 | 5.290 | 5.898 | 7.042 | 6.781 |
| Inventories | 44.247 | 27.796 | 25.136 | 21.837 | 12.339 | 9.785 | 4.023 | 3.405 | 4.297 | 4.682 |
| Receivables | 2.108 | 708 | 696 | 1.235 | 1.060 | 1.909 | 1.038 | 1.042 | 1.796 | 1.894 |
| Cash | 994 | 1.688 | 2.004 | 4.977 | 172 | 2.055 | 229 | 1.452 | 949 | 205 |
| Shareholders Funds | -31.069 | -26.808 | -32.977 | -42.044 | -49.612 | -55.828 | -67.192 | -80.713 | -88.487 | -103.749 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 78.418 | 57.000 | 60.813 | 70.093 | 63.182 | 69.577 | 72.481 | 86.612 | 98.624 | 112.310 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4751 - 4751" | |||||||||
| CAEN Financial Year |
4751
|
|||||||||
Comments - Elpiramyd 2008 Srl